 Home > Medical News > Latest Medical News > Announcement of latest persistence and booster data for Clover's new coronary pneumonia adjuvanted protein vaccine

Announcement of latest persistence and booster data for Clover's new coronary pneumonia adjuvanted protein vaccine

 Last Update: 2022-05-18
 Source: Internet
 Author: User

Tags

flu vaccine available

levels protein folding

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Cube Info

On April 18, Clover announced the company's adjuvant protein vaccine SCB-2019 (CpG 1018/aluminum adjuvant) at the 2022 World Vaccine Congress Washington 2022.

Clover Bio's new crown vaccine candidate consists of SCB-2019 antigen combined with two adjuvants, namely Dynavax's CpG 1018 adjuvant and aluminum hydroxide (aluminum adjuvant)

A new dataset from an extended follow-up analysis confirms earlier findings and shows high and durable protection in individuals approximately 6 months after basal immunization with SCB-2019 (CpG 1018/aluminum adjuvant)

Durability of protective efficacy for approximately 6 months after primary immunization

About 6 months after primary immunization, in adults (18-59 years old) without a history of 2019-nCoV infection, the protective efficacy against severe illness remained 100% and the protective efficacy against hospitalization was 95%

In individuals previously infected with 2019-nCoV, the protective efficacy against 2019-nCoV of any severity caused by any 2019-nCoV strain was 71% after primary immunization, and no clinical evidence of 2019-nCoV infection was observed over a period of approximately 6 months A trend of decreasing efficacy

Up-to-date heterologous booster needle data in the extended dataset

Among individuals previously vaccinated with two doses of AstraZeneca's Covid-19 vaccine, the heterologous booster vaccinated with SCB-2019 (CpG 1018/aluminum adjuvant) induced higher levels of neutralizing antibodies against the prototype strain than those vaccinated with three doses of AstraZeneca vaccine.

In individuals previously vaccinated with two doses of AstraZeneca's new crown vaccine, the level of neutralizing antibody induced by the heterologous booster shot with SCB-2019 (CpG 1018/aluminum adjuvant) was higher than that of the three doses of AstraZeneca Individuals with the Likang vaccine were about 3 times higher

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.